Brandon Capital Partners overview
Stories about Brandon Capital Partners
Aussie life science venture firm Brandon Capital opens U.S. office
Australian life science venture firm Brandon Capital Partners has opened a new office in Palo Alto, California. J. Leighton Read has joined the firm as a venture partner and will head the Palo Alto office.
Brandon Capital MRCF fund raises $154.4 mln
Brandon Capital said Monday that its Medical Research Commercialisation Fund closed at AU$200 million (US$154.4 million). Existing MRCF Investors AustralianSuper and Statewide Super participated. Hesta, an existing investor in Brandon funds, took part as well HOSTPLUS. Around AU$50M of the new fund will be reserved for 20 to 30 very early seed stage investments in biotech or medical device technologies.
Signostics Raises $4 Million
Signostics Inc., a Palo Alto, Calif.-based developer of ultrasound devices, has raised $4 million in new VC funding from Australian VC firms Brandon Capital Partners, Playford Capital and Terra Rossa Capital. The company had previously raised $9 million.
Brandon Capital Partners contact information
Offices
Level 9, 31 Queen Street, Melbourne, 3000, AustraliaContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Robert Sicilia | Job titleHead of Investor Relations | LocationMelbourne, Australia | Email  -------- |
| Mr. Dom Marot | Job titleChief Financial Officer | LocationMelbourne, Australia | Email --------- |
| Dr. Chris Nave | Job titleFounding Partner and Managing Director | LocationMelbourne, Australia | Email ------ |
| Dr. Stephen Thompson | Job titleFounding Partner and Managing Director | LocationSydney, Australia | Email -------- |
Brandon Capital Partners funds managed
Closed funds: 7
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ------- | Close dateJul 2025 | Strategy ------ | |
Fund size ----- | Close dateMay 2019 | Strategy ----- | |
Fund size --------- | Close dateApr 2015 | Strategy ---------- | |
Stories that mention Brandon Capital Partners
Allay Therapeutics scores $60m Series C
Allay Therapeutics, a clinical-stage biotechnology company, has raised $60 million in Series C financing.
Myricx nabs seed funding
UK-based Myricx Pharma, a drug discovery company, has secured 4.5 million pounds in seed financing.
Glyscend Therapeutics rakes in $20.5m Series A
Baltimore-based Glyscend Therapeutics, a developer of novel treatments for type 2 diabetes and related metabolic conditions, has closed $20.5 million in Series A financing.
EBR Systems nets $30 mln
Silicon Valley-based EBR Systems, a developer of a wireless cardiac pacing system for heart failure, has secured $30 million in funding. Brandon Capital Partners and M.H. Carnegie & Co. led the round. In conjunction with the funding, EBR Systems has appointed John McCutcheon as president and CEO.
Elastagen snags A$13 mln Series B
Elastagen Pty Ltd, an Australian developer of products based on recombinant human tropoelastin platform technology, has raised A$13 milion in Series B funding. The investors included Korea Investment Partners, AMOREPACIFIC Ventures, Wellcome Trust, Brandon Capital Partners, GBS Ventures and ATP Innovations. In addition to the funding, Sangwoo Lee of KIP has been added to Elastagen's board of directors.
Novartis to buy Spinifex for $200 mln
Novartis International AG has agreed to buy Spinifex Pharmaceuticals Inc. for an upfront cash consideration of $200 million plus undisclosed clinical development and regulatory milestone payments. based in Stamford, Connecticut and Melbourne, Australia, Spinifex develops drugs for the treatment of chronic pain. Deutsche Bank advised Spinifex. Spinifex's investors include Novo A/S, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest (University of Queensland, Australia).
Auspherix raises $9.2 mln
Auspherix Limited (UK) has raised £6 million (US$9.2 million) in a Series A venture financing. Imperial Innovations plc led the round alongside Australian founding investor the Medical Research Commercialisation Fund. Stevenage, United Kingdom-based Auspherix is an an early stage anti-infectives company.
Australia’s Medical Research Commercialisation Fund invests in Auspherix
Auspherix Pty Ltd said Thursday it has secured another AU$1 million (US$878,215) in a series A financing from Australia’s Medical Research Commercialisation Fund. Auspherix, of Sydney, is an early stage anti-infectives company developing antibiotics to treat resistant bacterial disease.